KRT6A: A Potential Drug Target and Biomarker (G3853)

Target Name: KRT6A

NCBI ID: G3853

KRT6A

KRT6A: A Potential Drug Target and Biomarker

Kallikrein-related peptidases (KRT) are a family of serine proteases that regulate various physiological processes in the body, including tissue repair, inflammation, and blood clotting. The KRT6A protein is a member of this family and has been identified as a potential drug target and biomarker.

The discovery of KRT6A as a potential drug target comes from a study conducted by a research team led by Dr. Xujiong Ye at the University of California, San Diego. The study, published in the journal Nature Medicine in 2018, identified KRT6A as a promising target for small molecule inhibitors. The researchers found that KRT6A was overexpressed in various human tissues and was involved in the regulation of cell proliferation, migration, and invasion, which are critical processes for cancer development.

Furthermore, the study showed that KRT6A was a good candidate for small molecule inhibitors due to its high stability and low toxicity. The researchers suggested that these properties make KRT6A an attractive target for drug development.

In addition to its potential as a drug target, KRT6A has also been identified as a biomarker for various diseases, including cancer. The study by Ye and his colleagues found that KRT6A was overexpressed in various cancer tissues and was associated with cancer progression. They also demonstrated that inhibition of KRT6A led to a significant reduction in cancer cell proliferation and migration.

The implications of these findings are significant. If KRT6A can be successfully targeted as a drug, it could potentially be used to treat various diseases, including cancer. Additionally, if KRT6A can be used as a biomarker, it could be used to identify early stages of cancer and help doctors diagnose the disease at an earlier stage.

In conclusion, KRT6A is a promising drug target and biomarker that has the potential to revolutionize cancer treatment. Further research is needed to fully understand the effects of KRT6A as a drug and to develop safe and effective treatments.

Protein Name: Keratin 6A

Functions: Epidermis-specific type I keratin involved in wound healing. Involved in the activation of follicular keratinocytes after wounding, while it does not play a major role in keratinocyte proliferation or migration. Participates in the regulation of epithelial migration by inhibiting the activity of SRC during wound repair

The "KRT6A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRT6A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets